AEON — AEON Biopharma, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1837607 ·
Last close
$0.11
Market Cap
$5.66M
52W High
$1.45
52W Low
$0.11
ADV30
1,187,205
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -5,929,000 -1,155,000 5,910,000 3,431,000 21,271,000
Mar 2026 0 — -5,937,000 -11,793,000 8,630,000 6,243,000 25,382,000
Dec 2025 0 — -5,501,000 -37,137,000 5,560,000 3,006,000 60,587,000
Sep 2025 0 — -2,530,000 -4,538,000 8,734,000 5,927,000 28,606,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,642,000
Investing CF
$0
Financing CF
$8,634,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.30
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-483,767,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-19,897,000
Pretax Income TTM
$-54,623,000
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -16,302,000 -39,222,000 5,560,000 60,587,000 -55,027,000 -17,308,000
Dec 2024 0 -27,824,000 42,005,000 3,142,000 31,711,000 -28,569,000 -20,292,000
Dec 2023 — — — 6,845,000 159,889,000 -153,044,000 —
Dec 2022 0 -48,429,000 -52,556,000 10,778,000 281,191,000 -287,500,000 -35,584,000
Dec 2021 0 -36,881,000 -55,637,000 — — — -28,433,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-54,623,000
OpCashFlow TTM
—
Assets (Latest)
$5,910,000
Forward EPS
$-0.27

Peers — same industry

TickerNameMarket CapLastDaily %
OTLC Oncotelic Therapeutics, Inc. $5.72M $0.01 —
INBP INTEGRATED BIOPHARMA INC $5.59M $0.18 —
GTBP GT Biopharma, Inc. $5.74M $3.18 —
INNPF INNOCAN PHARMA Corp $5.80M $1.29 —
ALZN Alzamend Neuro, Inc. $5.45M $1.13 —

News headlines (Yahoo Finance, 1h cache)

AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
2026-11-09 13:00 · Yahoo
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
2026-10-09 20:15 · Yahoo
AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar
2026-10-05 09:36 · Yahoo
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
2026-09-09 12:00 · Yahoo
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
2026-08-24 12:00 · Yahoo
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 20:15 · Yahoo
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
2026-08-03 20:15 · Yahoo
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
2026-07-14 12:00 · Yahoo
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
2026-04-03 20:05 · Yahoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
2026-06-04 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.